Mutation of regulatory phosphorylation sites in pfkfb2 does not affect the anti-fibrotic effect of metformin in the kidney

HIGHLIGHTS

• who: Geoff Harley and collaborators from the Kidney Laboratory, Department of Nephrology, Austin Health, Heidelberg, VIC, Australia, Department of Medicine, The University of Melbourne, Heidelberg, VIC, Australia have published the paper: Mutation of regulatory phosphorylation sites in PFKFB2 does not affect the anti-fibrotic effect of metformin in the kidney, in the Journal: PLOS ONE of 25/Nov/2021
• what: The authors attempted to determine whether the anti-fibrotic effect of metformin was also dependent on regulation of glycolysis. The authors demonstrated that metformin continues to have its protective effects in the UUO model of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.